Masatoshi Kudo, MD from Kindai University, Japan discusses TACE + Sorafenib may change standard in HCC and if overall survival data is positive then standard of care will change at the 2018 Gastrointestinal Cancers Symposium.
TACE + Sorafenib May Change Standard in HCC – If Overall Survival Data is Positive then Standard of Care Will Change
